Monoclonal gammopathy of undetermined significance (MGUS) occurs in 4% of the population over 50 years old and represents a precursor lesion to myeloma. Although several studies have examined the immune response to antigens in human cancer including myeloma, the nature of immune response against preneoplastic lesions is less studied. This application builds on our recent findings that a large proportion of patients with MGUS harbor spontaneous immune responses against antigens expressed on embryonal / cancer stem cells. In preliminary studies, the detection of these responses predicted reduced probability of disease progression. The specific objectives of the studies in this application are 1) to better understand this naturally occurring immune response in MGUS;2) to further evaluate the basis of the absence of these responses in myeloma patients;and 3) to understand the clinical and prognostic significance of immunity to stem cell antigens in these patients in the context of a prospective clinical trial. These studies have direct implications for approaches to boost host immunity against myeloma stem cells and harnessing properties of host response for risk assessment and early detection of cancer.

Public Health Relevance

The goal of these studies is to understand the properties of naturally occurring immune responses against cancer stem cells in people without cancer. Harnessing such responses may be important for prevention of cancer, such as myeloma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Jessup, John M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
Internal Medicine/Medicine
Schools of Medicine
New Haven
United States
Zip Code
Nair, Shiny; Branagan, Andrew R; Liu, Jun et al. (2016) Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med 374:555-61
Dhodapkar, Madhav V; Sexton, Rachael; Das, Rituparna et al. (2015) Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood 126:2475-8
Sureshbabu, Angara; Syed, Mansoor A; Boddupalli, Chandra Sekhar et al. (2015) Conditional overexpression of TGF?1 promotes pulmonary inflammation, apoptosis and mortality via TGF?R2 in the developing mouse lung. Respir Res 16:4
Nair, Shiny; Boddupalli, Chandra Sekhar; Verma, Rakesh et al. (2015) Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood 125:1256-71
Das, Rituparna; Verma, Rakesh; Sznol, Mario et al. (2015) Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194:950-9
Zhao, S; Choi, M; Heuck, C et al. (2014) Serial exome analysis of disease progression in premalignant gammopathies. Leukemia 28:1548-52
Sehgal, Kartik; Dhodapkar, Kavita M; Dhodapkar, Madhav V (2014) Targeting human dendritic cells in situ to improve vaccines. Immunol Lett 162:59-67
Sehgal, Kartik; Ragheb, Ragy; Fahmy, Tarek M et al. (2014) Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk. J Immunol 193:2297-305
Dhodapkar, Madhav V; Sexton, Rachael; Waheed, Sarah et al. (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123:78-85
Dhodapkar, Madhav V (2013) Personalized immune-interception of cancer and the battle of two adaptive systems--when is the time right? Cancer Prev Res (Phila) 6:173-6

Showing the most recent 10 out of 23 publications